Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00424892 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome
A Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 600
- Enrollment target
NCT00424892 is a Phase 2 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 600 participants.
The verdict
NCT00424892, a Phase 2 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 600 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the long-term safety of desvenlafaxine succinate sustained-release (DVS SR) during open-label treatment in adult outpatients with fibromyalgia syndrome.
Interventions
- DRUG Desvenlafaxine Sustained Release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00424892
The ClinicalTrials.gov registry entry for NCT00424892 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Desvenlafaxine Sustained Release is the first listed.
NCT00424892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00424892 about?
NCT00424892 is a clinical study titled "Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome". The primary objective is to evaluate the long-term safety of desvenlafaxine succinate sustained-release (DVS SR) during open-label treatment in adult outpatients with fibromyalgia syndrome.
What is the current status of trial NCT00424892?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 600 participants. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00424892?
The interventions under investigation include: Desvenlafaxine Sustained Release (DRUG).
Who is sponsoring clinical trial NCT00424892?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.